References
- Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670–1681 (2010).
- Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. 46(7), 1225–1228 (2005).
- Schoenhagen P, Nissen SE. Coronary atherosclerotic disease burden: an emerging endpoint in progression/regression studies using intravascular ultrasound. Curr. Drug Targets. Cardiovasc. Haematol. Disord. 3(3), 218–226 (2003).
- Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am. J. Cardiol. 82(9A), 3Q–12Q (1998).
- Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345(22), 1583–1592 (2001).
- Nicholls SJ, Hsu A, Wolski K et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J. Am. Coll. Cardiol. 55(21), 2399–2407 (2010).
- Stone GW, Maehara A, Lansky AJ et al.; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364(3), 226–235 (2011).
- Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 291(2), 210–215 (2004).
- Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch. Intern. Med. 164(12), 1285–1292 (2004).
- Hoffmann U, Moselewski F, Cury RC et al. Predictive value of 16-slice multidetector spiral computed tomography to detect significant obstructive coronary artery disease in patients at high risk for coronary artery disease: patient versus segment-based analysis. Circulation 110(17), 2638–2643 (2004).
- Nissen SE, Tuzcu EM, Schoenhagen P et al.; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291(9), 1071–1080 (2004).
- Nissen SE, Nicholls SJ, Sipahi I et al.; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295(13), 1556–1565 (2006).
- Serruys PW, García-García HM, Buszman P et al.; Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118(11), 1172–1182 (2008).
- Corti R, Fuster V, Fayad ZA et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106(23), 2884–2887 (2002).
- Hyafil F, Cornily JC, Feig JE et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat. Med. 13(5), 636–641 (2007).
- Lee JM, Robson MD, Yu LM et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J. Am. Coll. Cardiol. 54(19), 1787–1794 (2009).
- Fayad ZA, Mani V, Woodward M et al.; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378(9802), 1547–1559 (2011).